Insulin-like growth factor- dependent proliferation and survival of triple-negative breast cancer cells: Implications for therapy

Neoplasia

Volumn 13, Issue 6, 2011, Pages 504-515

  Davison, Zoë ^a   de Blacquière, Gail E ^a   Westley, Bruce R ^a   May, Felicity E B ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; INSULIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROGESTERONE RECEPTOR; PROTEIN KINASE B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; STAUROSPORINE;

ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER;

EID: 79958120631     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.101590     Document Type: Article

References (52)

1. Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, and Carey LA (2008). Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 14(24), 8010-8018.
2. Reis-Filho JS and Tutt AN (2008). Triple negative tumours: a critical review. Histopathology 52(1), 108-118.
3. Rakha EA, Reis-Filho JS, and Ellis IO (2008). Basal-like breast cancer: a critical review. J Clin Oncol 26, 2568-2581.
4. Bauer KR, Brown M, Cress RD, Parise CA, and Caggiano V (2007). Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 109(9), 1721-1728.
5. Stead LA, Lash TL, Sobieraj JE, Chi DD, Westrup JL, Charlot M, Blanchard RA, Lee JC, King TC, and Rosenberg CL (2009). Triple negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res 11(2), R18.
6. Bowen RL, Duffy SW, Ryan DA, Hart IR, and Jones JL (2008). Early onset of breast cancer in a group of British black women. Br J Cancer 98, 277-281.
7. Minn AJ, Gupta GP, Siegel PM, Bos PD, ShuW, Giri DD, Viale A, Olshen AB, Gerald WL, and Massagué J (2005). Genes that mediate breast cancer metastasis to lung. Nature 436, 518-524.
8. Luck AA, Evans AJ, Green AR, Rakha EA, Paish C, and Ellis IO (2008). The influence of basal phenotype on the metastatic pattern of breast cancer. Clin Oncol R Coll Radiol 20, 40-45.
9. Foulkes WD, Stefansson IM, Chappuis PO, Bégin LR, Goffin JR, Wong N, Trudel M, and Akslen LA (2003). Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95(19), 1482-1485.
10. Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al. (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100(14), 8418-8423.
11. Banerjee S, Reis-Filho JS, Ashley S, Steele D, Ashworth A, Lakhani SR, and Smith IE (2006). Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol 59, 729-735.
12. Sirohi B, Arnedos M, Popat S, Ashley S, Nerurkar A, Walsh G, Johnston S, and Smith IE (2008). Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 19(11), 1847-1852.
13. Myers MG Jr, Sun XJ, and White MF (1994). The IRS-1 signaling system. Trends Biochem Sci 19, 289-293.
14. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, and Pollak M (1998). Circulating concentrations of insulinlike growth factor-I and risk of breast cancer. Lancet 351(9113), 1393-1396.
15. Schernhammer ES, Holly JM, Pollak MN, and Hankinson SE (2005). Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 14(3), 699-704.
16. Renehan AG, Harvie M, and Howell A (2006). Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. Endocr Relat Cancer 3(2), 273-278.
17. Pollak M (2008). Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8(12), 915-928.
18. Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, Tengowski MW, Wang F, Gualberto A, Beebe JS, et al. (2005). Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11(5), 2063-2073.
19. Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, and Ludwig DL (2007). IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 13(18 pt 2), 5549s-5555s.
20. Wang Y, Hailey J, Williams D, Wang Y, Lipari P, Malkowski M, Wang X, Xie L, Li G, Saha D, et al. (2005). Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol Cancer Ther 4(8), 1214-1221.
21. Carboni JM, Wittman M, Yang Z, Lee F, Greer A, Hurlburt W, Hillerman S, Cao C, Cantor GH, Dell-John J, et al. (2009). BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol Cancer Ther 8(12), 3341-3349.
22. Sabbatini P, Rowand JL, Groy A, Korenchuk S, Liu Q, Atkins C, Dumble M, Yang J, Anderson K, Wilson BJ, et al. (2009). Antitumor activity ofGSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase. Clin Cancer Res 15, 3058-3067.
23. Stewart AJ, Johnson MD, May FEB, and Westley BR (1990). Role of insulinlike growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem 265(34), 21172-21178.
24. Stewart AJ, Westley BR, and May FEB (1992). Modulation of the proliferative response of breast cancer cells to growth factors by oestrogen. Br J Cancer 66, 640-648.
25. Westley BR, Clayton SJ, Daws MR, Molloy CA, and May FEB (1998). Interactions between the oestrogen and insulin-like growth factor signalling pathways in the control of breast epithelial cell proliferation. Biochem Soc Symp 63, 35-44.
26. Yee D and Lee AV (2000). Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J Mammary Gland Biol Neoplasia 5(1), 107-115.
27. Sisci D and Surmacz E (2007). Crosstalk between IGF signaling and steroid hormone receptors in breast cancer. Curr Pharm Des 13(7), 705-717.
28. Bartucci M, Morelli C, Mauro L, Ando S, and Surmacz E (2001). Differential insulin-like growth factor I receptor signalling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Cancer Res 61, 6747-6754.
29. Sepp-Lorenzino L, Rosen N, and Lebwohl DE (1994). Insulin and insulin-like growth factor signaling are defective in the MDA MB-468 human breast cancer cell line. Cell Growth Differ 5(10), 1077-1083.
30. Jackson JG and Yee D (1999). IRS-1 expression and activation are not sufficient to activate downstream pathways and enable IGF-I growth response in estrogen receptor negative breast cancer cells. Growth Horm IGF Res 9(5), 280-289.
31. Oh Y, Müller HL, Lamson G, and Rosenfeld RG (1993). Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem 268(20), 14964-14971.
32. Chambers AF (2009). MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Res 69(13), 5292-5293.
33. Hollestelle A, Nagel JH, Smid M, Lam S, Elstrodt F, Wasielewski M, Ng SS, French PJ, Peeters JK, Rozendaal MJ, et al. (2010). Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res Treat 121(1), 53-64.
34. Molloy CA, May FEB, and Westley BR (2000). Insulin receptor substrate-1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line. J Biol Chem 275(17), 12565-12571.
35. de Blaquière GE, May FEB, and Westley BR (2009). Increased expression of both insulin receptor substrates 1 and 2 confers increased sensitivity to IGF-1 stimulated cell migration. Endocr Relat Cancer 16(2), 635-647.
36. Daws MR, Westley BR, and May FEB (1996). Paradoxical effects of overexpression of the type I insulin like growth factor receptor on the responsiveness of breast cancer cells to IGFs and estradiol. Endocrinology 137, 1177-1186.
37. May FEB and Westley BR (1988). Identification and characterisation of estrogenregulated RNAs in human breast cancer cells. J Biol Chem 263, 12901-12908.
38. Otto WR (2005). Fluorimetric DNA assay of cell number. Methods Mol Biol 289, 251-262.
39. Arpino G, Gutierrez C, Weiss H, Rimawi M, Massarweh S, Bharwani L, De Placido S, Osborne CK, and Schiff R (2007). Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HERtargeted therapy. J Natl Cancer Inst 99(9), 694-705.
40. Healicon RM, Westley BR, and May FEB (1993). Isolation and characterization of an oestrogen-responsive breast-cancer cell line, EFF-3. Int J Cancer 53(3), 388-394.
41. Westley BR, Holzel F, and May FEB (1989). Effects of oestrogen and the antioestrogens, tamoxifen and LY117018, on four oestrogen-regulated RNAs in the EFM-19 breast cancer cell line. J Steroid Biochem 32(3), 365-372.
42. May FEB, Johnson MD, Wiseman LR, Wakeling AE, Kastner P, and Westley B (1989). Regulation of progesterone receptor mRNA by oestradiol and antioestrogens in breast cancer cell lines. J Steroid Biochem 33, 1035-1041.
43. Papa V, Gliozzo B, Clark GM, McGuire WL, Moore D, Fujita-Yamaguchi Y, Vigneri R, Goldfine ID, and Pezzino V (1993). Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 53(16), 3736-3740.
44. Surmacz E (2000). Function of the IGF-I receptor in breast cancer. J Mammary Gland Biol Neoplasia 5(1), 95-105.
45. Arteaga CL, Kitten LJ, Coronado EB, Jacobs S, Kull FC Jr, Allred DC, and Osborne CK (1989). Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 84(5), 1418-1423.
46. Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE, et al. (2008). Phosphorylated insulin-like growth factor-I/ insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68(24), 10238-10246.
47. Bonneterre J, Peyrat JP, Beuscart R, and Demaille A (1990). Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer. Cancer Res 50(21), 6931-6935.
48. Klinakis A, Szabolcs M, Chen G, Xuan S, Hibshoosh H, and Efstratiadis A (2008). Igf1r as a therapeutic target in a mouse model of basal-like breast cancer. Proc Natl Acad Sci USA 105(49), 19378-19383.
49. Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, and Lee AV (2008). Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol 26(25), 4078-4085.
50. Greene MW, Sakaue H, Wang L, Alessi DR, and Roth RA (2003). Modulation of insulin-stimulated degradation of human insulin receptor substrate-1 by serine 312 phosphorylation. J Biol Chem 278(10), 8199-8211.
51. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, and Harbeck N (2009). Triple-negative breast cancer-current status and future directions. Ann Oncol 20(12), 1913-1927.
52. Gualberto A (2010). Figitumumab (CP-751,871) for cancer therapy. Expert Opin Biol Ther 10(4), 575-585.